Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, Total tau, and P-tau181 for identifying alzheimer disease amyloid plaque pathology

Archives of Neurology

Volumn 68, Issue 9, 2011, Pages 1137-1144

  Fagan, Anne M ^a   Shaw, Leslie M ^c   Xiong, Chengjie ^a   Vanderstichele, Hugo ^d   Mintun, Mark A ^a,b   Trojanowski, John Q ^c   Coart, Els ^a,d   Morris, John C ^a   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d INNOGENETICS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; PHOSPHORYLATED TAU 181 PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NEUROFIBRILLARY TANGLE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PLAQUE, AMYLOID; TAU PROTEINS;

EID: 80052775337     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.105     Document Type: Article

References (36)

1. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical"Alzheimer's disease. Ann Neurol. 1999;45(3):358-368. (Pubitemid 29120041)
2. Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998;57(12):1168-1174. (Pubitemid 28562746)
3. Price JL, McKeel DW Jr, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30(7):1026-1036.
4. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944. (Pubitemid 14076461)
5. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1143-1153. (Pubitemid 32405708)
6. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx. 2004;1(2):213-225. (Pubitemid 46589353)
7. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006; 59(3):512-519. (Pubitemid 43358072)
8. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29(10):1456-1465.
9. Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med. 2009; 1(8-9):371-380.
10. Tolboom N, Van der Flier WM, Yaqub M, et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med. 2009;50(9):1464-1470.
11. Grimmer T, Riemenschneider M, Förstl H, et al. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry. 2009;65(11):927-934.
12. Jagust WJ, Landau SM, Shaw LM, et al Alzheimer's Disease Neuroimaging Initiative. Relationships between biomarkers in aging and dementia. Neurology. 2009; 73(15):1193-1199.
13. Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66(3):382-389.
14. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306-319. (Pubitemid 38269583)
15. Morris JC, McKeel DW Jr, Fulling K, Torack RM, Berg L. Validation of clinical diagnostic criteria for Alzheimer's disease. Ann Neurol. 1988;24(1):17-22.
16. Berg L, McKeel DW Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55 (3):326-335.
17. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.
18. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403-413.
19. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446-452.
20. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16(5):834-840. (Pubitemid 26292051)
21. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122-131.
22. Steiger JH. Tests for comparing elements of a correlation matrix. Psychol Bull. 1980;87(2):245-251. doi:10.1037/0033-2909.87.2.245.
23. McClish DK. Analyzing a portion of the ROC curve. Med Decis Making. 1989;9(3): 190-195.
24. Zhou X, Obuchowski N, McClish D. Statistical Methods in Diagnostic Medicine. New York, NY: Wiley-Interscience; 2002.
25. Olsson A, Vanderstichele H, Andreasen N, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2005;51(2):336-345. (Pubitemid 40175803)
26. Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature. 2009;461(7266):916-922.
27. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9(11):1118-1127.
28. Reijn TS, Rikkert MO, Van Geel WJ, De Jong D, Verbeek MM. Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid β(42) and tau proteins. Clin Chem. 2007;53(5):859-865. (Pubitemid 46744241)
29. Lewczuk P, Kornhuber J, Vanderstichele H, et al. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: amulticenter study. Neurobiol Aging. 2008;29(6):812-818. (Pubitemid 351601894)
30. Forsberg A, Almkvist O, Engler H, Wall A, Långström B, Nordberg A. High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res. 2010;7(1): 56-66.
31. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/β-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343-349. (Pubitemid 46425688)
32. Li G, Sokal I, Quinn JF, et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69(7):631-639. (Pubitemid 47256004)
33. Craig-Schapiro R, Perrin RJ, Roe CM, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry. 2010;68(10):903-912.
34. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228-234. (Pubitemid 43238346)
35. Snider BJ, Fagan AM, Roe C, et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol. 2009; 66(5):638-645.
36. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302 (4):385-393.